BPC-157 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Bovine serum albumin (BSA or "Bovine Fraction V") is a serum albumin protein derived from cows. It is often used as a protein concentration standard in lab experiments. The nickname "Fraction V" refers to albumin being the fifth fraction of the original Edwin Cohn purification methodology that made use of differential solubility characteristics of plasma proteins. By manipulating solvent concentrations, pH, salt levels, and temperature, Cohn was able to pull out successive "fractions" of blood plasma. The process was first commercialized with human albumin for medical use and later adopted for production of BSA.
== Patents == "Coaxial Flow Post Capillary Mixing", J.W. Jorgenson and D.J. Rose, U.S. Patent No. 4,936,974. "Microelectrospray Method and Apparatus", J.W. Jorgenson and D.M. Dohmeier, U.S. Patent No. 5,115,131. "Two-Dimensional High-Performance Liquid Chromatography/Capillary Electrophoresis", J.W. Jorgenson and M.M. Bushey, U.S. Patent No. 5,131,998. "Two-Dimensional High-Performance Liquid Chromatography/Capillary Electrophoresis", J.W. Jorgenson and M.M. Bushey, U.S. Patent No. 5,240,577. "Method and Device for High Speed Separation of Complex Molecules", J.W. Jorgenson and C.A. Monnig, U.S. Patent No. 5,269,900. "Two-Dimensional Separation System", J.W. Jorgenson and A.V. Lemmo, U.S. Patent No. 5,389,221. "Two-Dimensional Separation System", J.W. Jorgenson and A.V. Lemmo, U.S. Patent No. 5,496,460. “Sample injector system for liquid chromatography”, Gerhardt; Geoff C., Jorgenson; James W., Fadgen; Keith, U.S. Patent No. 8,173,070
In cancerous cells, initiation factors assist in cellular transformation and development of tumors. The survival and growth of cancer is directly related to the modification of initiation factors and is used as a target for pharmaceuticals. Cells need increased energy when cancerous and derive this energy from proteins. Over-expression of initiation factors correlates with cancers, as they increase protein synthesis for proteins needed in cancers. Some initiation factors, such as eIF4E, are important in synthesizing specific proteins needed for the proliferation and survival of cancer. The careful selection of proteins ensures that proteins that are usually limited in translation and only proteins needed for cancer cell growth will be synthesized. This includes proteins involved in growth, malignancy, and angiogenesis. The eIF4E factor, along with eIF4A and eIF4G, also play a role in transitioning benign cancer cells to metastatic. The largest initiation factor, eIF3, is another significant initiation factor in human cancers. Due to its role in creating the 43S pre-initiation complex, it helps to bind the ribosomal subunit to the mRNA. The initiation factor has been linked to cancers through over-expression. For example, one of the thirteen eIF3 proteins, eIF3c, interacts with and represses proteins used in tumor suppression. Limited expression of certain eIF3 proteins, such as eIF3a an eIF3d, has been proven to decrease the vigorous growth of cancer cells. The over-expression of eIF3a has been linked to breast, lung, cervix, esophagus, stomach, and colon cancers.
The densities of the two phases must also be sufficiently different so that the phases will move past each other in the column. Many DCCC solvent systems contain both chloroform and water. The solvent system used in the seminal publication was made from chloroform, acetic acid, and aqueous 0.1 M hydrochloric acid. Many subsequent solvents systems were made with chloroform, methanol, and water which is sometimes represented as a ChMWat solvent system. Solvent systems formulated with ''n''-butanol, water and a modifier such as acetic acid, pyridine or n-propanol have also enjoyed some success in DCCC. In some cases, non-aqueous biphasic solvent systems such as acetonitrile and methanol have been utilized. The main difference between DCCC and other types of countercurrent chromatography techniques is that there is no vigorous mixing of phases to enhance the mass transfer of compounds that allows them to distribute between the two phases. In 1951 Kies and Davis described an apparatus similar to the DCCC. They created a series of open tubes that were arranged in a cascade to either drip a more dense phase through a less dense stationary phase or, conversely, a less dense phase could be introduced into the bottom of the tube to dribble through the more dense phase. In 1954, a fractionation column was introduced by Kepes the resembled a CCC column divided into chambers with perforated plastic disks. Similar DCCC-type instruments have been created by A. E. Kostanyan and collaborators which employ vertical columns that are divided into partitions with porous disks.
Sources: en.wikipedia.org
Any single cycle is longer than 90 days, as long as the individual is at least one year post menarche. The cycle is generally shorter than 21 days or longer than 45 days, as long as the individual is at least one year post menarche. The cycle is generally longer than 35 days, as long as the individual is at least three years post menarche. Amenorrhea which is not due to another underlying cause, as long as the individual is at least 15 years old or at least 3 years post thelarche. Biochemical androgen excess in PMOS is assessed using total and free testosterone. Accurate measurement requires tandem mass spectrometry assays, as direct free testosterone tests are not reliable. Interpretation is based on laboratory reference ranges. Hormonal contraception can interfere with hormone levels, so a withdrawal period of at least three months with alternative contraception may be needed. Severely elevated androgen levels may indicate other conditions.
Little prolactin—the predominant form. It has a molecular weight of approximately 23-kDa. It is a single-chain polypeptide of 199 amino acids and is apparently the result of removal of some amino acids. Big prolactin—approximately 48 kDa. It may be the product of interaction of several prolactin molecules. It appears to have little, if any, biological activity. Macroprolactin—approximately 150 kDa. It appears to have a low biological activity. Other variants with the molecular masses of 14, 16, and 22 kDa. The levels of larger ones are somewhat higher during the early postpartum period.
== Process == The first step of the PEGylation is the suitable functionalization of the PEG polymer at one or both ends. PEGs that are activated at each end with the same reactive moiety are known as "homobifunctional", whereas if the functional groups present are different, then the PEG derivative is referred as "heterobifunctional" or "heterofunctional". The chemically active or activated derivatives of the PEG polymer are prepared to attach the PEG to the desired molecule. The overall PEGylation processes used to date for protein conjugation can be broadly classified into two types, namely a solution phase batch process and an on-column fed-batch process. The simple and commonly adopted batch process involves the mixing of reagents together in a suitable buffer solution, preferably at a temperature between 4 and 6 °C, followed by the separation and purification of the desired product using a suitable technique based on its physicochemical properties, including size exclusion chromatography (SEC), ion exchange chromatography (IEX), hydrophobic interaction chromatography (HIC) and membranes or aqueous two-phase systems (ATPS). The choice of the suitable functional group for the PEG derivative is based on the type of available reactive group on the molecule that will be coupled to the PEG. For proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine and tyrosine.
Sources: en.wikipedia.org
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries. Remdesivir was originally developed to treat hepatitis C, and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID‑19. Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The most common side effect in healthy volunteers is raised blood levels of liver enzymes. The most common side effect in people with COVID‑19 is nausea. Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
FAs can be further processed in the endoplasmic reticulum, where they are joined to a glycerol backbone in groups of three to form triacylglycerol (TAG), or in pairs (with the addition of a polar head group on the C1 of glycerol) to form a phospholipid. Fatty acids are classified according to the number of carbon double bonds present about the aliphatic hydrocarbon chain. Saturated fatty acids have no double bonds. Monounsaturated fatty acids have one double bond, while polyunsaturated fatty acids have two or more double bonds present about the hydrocarbon chain. Saturated fatty acids are a primary constituent of glycerolipids, as well as the phospholipids and sphingolipids found in cellular membranes. Common saturated fatty acids include palmitic acid, butyric acid, and stearic acid, all of which contribute to LDL cholesterol levels and increase the risk of obesity, heart disease, and stroke. Monounsaturated fatty acids are also primary constituent of glycerolipids and cellular membrane structures. Monounsaturated fatty acids include oleic acid, palmitoleic acid, and vaccenic acid, which help lower LDL cholesterol and reduce the risk of heart disease and stroke. Polyunsaturated fatty acids are found in the phospholipids of cell membranes, and are also known to act as precursors for a variety of lipid signaling molecules. Common polyunsaturated fatty acids include the essential omega-3 and omega-6 fatty acids, which are crucial for brain, heart, and immune health.
ISO 2171: Cereals, pulses and by-products — Determination of ash yield by incineration; ISO 3593: Starch — Determination of ash; ISO 928: Spices and condiments - Determination of total ash; and ISO 936: Meat and meat products - Determination of total ash. Examples of ash content methods for the determination of ash in other solids include
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.